Long-term safety of anti-TNF-α in PsA patients with concomitant HCV infection: a retrospective observational multicenter study on 15 patients

[1]  D. Kaplan.  Immunopathogenesis of Hepatitis C Virus Infection. , 2015, Gastroenterology clinics of North America.

[2]  Chulhee Choi,et al.  Hepatitis C virus infection enhances TNFα‐induced cell death via suppression of NF‐κB , 2012, Hepatology.

[3]  L. Punzi,et al.  Infection relapse in spondyloarthritis treated with biological drugs: a single-centre study , 2012, Scandinavian journal of rheumatology.

[4]  P. Strazzullo,et al.  Psoriatic arthritis is associated with increased arterial stiffness in the absence of known cardiovascular risk factors: a case control study , 2012, Clinical Rheumatology.

[5]  I. Olivieri,et al.  Recommendations for the use of biologic therapy in the treatment of psoriatic arthritis: update from the Italian Society for Rheumatology. , 2011, Clinical and experimental rheumatology.

[6]  I. Olivieri,et al.  The effectiveness and safety of TNF-alpha blockers in the treatment of early psoriatic arthritis: an Italian multicentre longitudinal observational pilot study , 2011, Clinical Rheumatology.

[7]  R. Cattaneo,et al.  Treatment with etanercept in six patients with chronic hepatitis C infection and systemic autoimmune diseases. , 2008, Autoimmunity reviews.

[8]  A. Floreani,et al.  Changing Epidemiology of HCV and HBV Infections in Northern Italy: A Survey in the General Population , 2008, Journal of clinical gastroenterology.

[9]  M. Galeazzi,et al.  Safety of Cyclosporin A in HCV‐Infected Patients , 2007, Annals of the New York Academy of Sciences.

[10]  L. Punzi,et al.  Pathogenetic and clinical rationale for TNF-blocking therapy in psoriatic arthritis. , 2007, Autoimmunity reviews.

[11]  L. Calabrese,et al.  Biologic agents and liver toxicity: an added concern or therapeutic opportunity? , 2007, Nature Clinical Practice Rheumatology.

[12]  C. Zamboulis,et al.  Inhibition of TNFα does not induce viral reactivation in patients with chronic hepatitis C infection: two cases , 2006, Clinical Rheumatology.

[13]  Steven R. Cohen,et al.  Etanercept monotherapy for a patient with psoriasis, psoriatic arthritis, and concomitant hepatitis C infection. , 2006, Journal of the American Academy of Dermatology.

[14]  A. Gottlieb,et al.  Etanercept therapy for patients with psoriatic arthritis and concurrent hepatitis C virus infection: report of 3 cases. , 2004, Journal of the American Academy of Dermatology.

[15]  T. Prindiville,et al.  The biology of TNF blockade. , 2003, Autoimmunity reviews.

[16]  J. Smolen,et al.  Toxicity profiles of traditional disease modifying antirheumatic drugs for rheumatoid arthritis , 2003, Annals of the rheumatic diseases.

[17]  F. D'armiento,et al.  Microscopic inflammatory changes in colon of patients with both active psoriasis and psoriatic arthritis without bowel symptoms. , 2000, The Journal of rheumatology.

[18]  J. Prieto,et al.  Tumor necrosis factor α gene expression and the response to interferon in chronic hepatitis C , 1996, Hepatology.

[19]  H. Tilg,et al.  Serum levels of cytokines in chronic liver diseases. , 1992, Gastroenterology.

[20]  V. Wright,et al.  Psoriatic arthritis. , 1973, Seminars in arthritis and rheumatism.